17alpha-Estradiol;Alpha-estradiol17A-estradiol;CAS57-91-0ForAnti-agingSpecificati***17alpha-EstradiolHormonesForanti-agingfacecream17alpha-EstradiolSynonyms:Alpha-estradiol;17A-estradiolCAS:57-91-0EINECS:200-354-8MolecularFormula:C18H24O2MolecularWeight:272.39MolecularStructurer:Appearance:hiteoroff-whitecrystallinepowderAssay:99%min.Meltingrange:216-224oCSpecificrotation:+52oto+60oLossondrying:3.5%MAXMonorimpurity:0.2%MAXTotalimpurities:1.0%max17alpha-Estradiolisakindofestrogenthatcanpromoteandregulatethefemalesexorgansandsexualcharacteristicsofnormaldevelopment.Topromotedevelopmentofductalhyperplasia,butinlargerdoses,caninhibitthereleaseofanteriorpituitaryprolactin,andreductionofmilksecretion.Co***eceuticaluse:Anti-agingfacecreams.Storage:Storedincoolplace,keepcontainertightlyclosedinadryandwell-ventilatedplace.Shelflife:2yearsinunopenedcontainer.Description:Estradiol(calledα-estradiolor17α-estradiol)forhumanbreastcancercellsintissueculturebiologicallyactiveestrogen.Notpartofthe17-andselectiveestrogenreceptor(ER-X)traditionalhormone/receptoroftheendocrinesystem,butanimportantautocrine/paracrinefunctionofthesystemispartofthegrowthinthe***brain.Inmenopause,andneurodegenerativediseases(egAlzheimer'sdiseaseandischemicstroke)treatment,17-estradiolmayh***eimportantimplicati***forhormonereplacementtherapything.Thedevelopmentofsecondarysexcharacteristicsinwomenisdrivenbyestrogens,tobespecific,estradiol.Thesechangesareinitiatedatthetimeofpuberty,mostareenhancedduringthereproductiveyears,andbecomelesspronouncedwithdecliningestradiolsupportafterthemenopause.Thus,estradiolenhancesbreastdevelopment,andisresp***ibleforchangesinthebodyshape,affectingbones,jointsandfatdeposition.Fatstructureandskincompositionaremodifiedbyestradiol.Applicati***:Thismedicationisafemalehormone.Itisusedbywomentohelpreducesymptomsofmenopause(suchashotflashes,vaginaldryness).Thesesymptomsarecausedbythebodymakinglessestrogen.Ifyouareusingthismedicationtotreatsymptomsonlyinandaroundthevagina,productsapplieddirectlyinsidethevaginashouldbec***ideredbeforemedicati***thataretakenbymouth,absorbedthroughtheskin,orinjected.Certainestrogenproductsmayalsobeusedbywomenaftermenopausetopreventboneloss(osteoporosis).However,thereareothermedicati***(suchasbisphosphonatesincludingalendronate)thatarealsoeffectiveinpreventingbonelossandmaybesafer.Thesemedicati***shouldbec***ideredforusebeforeestrogentreatment.COA:ProductnameEstradiolAppearanceWhitecrystallinepowderCharacteristicsWhiteorcreamywhite,crystallinepowderconformMeltingpoint176-180¡ãC178~179¡ãCWater¡Ü3.5%passAssay97.0~103.0%99.3%Lossondrying¡Ü0.5%0.1%Relatedsubstancestotalimpurities¡Ü1.0%Passanyindividualimpurity¡Ü0.5%PassResidualsolventsethanol¡Ü0.5%Passskype:edisonxu0907emailtracyatycphardotcom)